Prevention of deep vein thrombosis in pre-trochanteric hip fracture

Comparison the Injectual Enoxaparin with Oral Rivaroxaban in DVT Prophylaxis of Patients with Pre-Trochanteric Hip Fracture

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190325043107N16

Enrollment

Registered

2019-12-22

Start date

2020-01-05

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep vein thrombosis. Acute embolism and thrombosis of deep veins of lower extremity

Interventions

Intervention 1: Intervention group: in the intervention group, after surgery, they will receive 40 mg of enoxaparin subcutaneously for 30 days (one daily). The enoxaparin ampoule will be purchased fro

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Presence of peri-trochanteric femur fracture

Exclusion criteria

Exclusion criteria: Heparin sensitivity Endocarditis Liver disease Hematologic diseases

Design outcomes

Primary

Measure	Time frame
Deep vein thrombosis. Timepoint: Once before the intervention and once at the end of the study (30 days later). Method of measurement: Take a blood test and check the level of D-Dimer in the blood.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Bazavar

Tabriz University of Medical Sciences

Mbazavar@yahoo.com+98 41 3335 7310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026